Andrin Oswald – AfricaNewsAnalysis

Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis

15/08/2013 ANA 0

Novartis announced today that the Australian Therapeutic Goods Administration (TGA) has added Bexsero®, a multi-component Meningococcal B (MenB) vaccine (recombinant, adsorbed) suspension for injection 0.5 ml pre-filled syringe, to the Australian Register of Therapeutic Goods […]

FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

02/08/2013 ANA 0

Novartis announced yesterday that the US Food and Drug Administration (FDA) approved Menveo® (Meningococcal Group A, C, W-135 and Y conjugate vaccine) for the prevention of meningococcal disease caused by four strains of the bacterium […]

UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease, following JCVI interim recommendation on Novartis Bexsero® vaccine

24/07/2013 ANA 0

Novartis is disappointed by the interim position of the UK Joint Committee on Vaccination and Immunisation (JCVI) to not recommend Bexsero®for inclusion in the National Immunisation Programme at this time, and does not believe that […]